Rogers Yongqing Luo

Chief Executive Officer

Mr. Luo was previously the president and general manager of Greater China of Brii Biosciences Limited (HKEX: 2137) from 11 September 2020 to 15 September 2022 and its executive director from 30 March 2021 to 15 September 2022, and the chief executive officer of a subsidiary of Brii Biosciences Limited, TSB Therapeutics, from December 2021 to 15 September 2022. From September 2016 to September 2020, he was the global vice president and general manager of China of Gilead Sciences, Inc., during which he helped to build Gilead Sciences, Inc.’s presence in China. He led the clinical development, regulatory approval process and successful commercial launch of eight innovative products as well as established a unique business model encompassing science, commercialization and patient access. Prior to that, he held senior positions in multiple multinational pharmaceutical companies including Roche and Novartis. 

Mr. Luo received his medical education from Xiangya School of Medicine, Central-South University, in China and graduated in July 1992, and then served for three years as a surgeon at St. Luke’s Hospital, Shanghai, from July 1992 to July 1995. He obtained an executive master of business administration from China Europe International Business School in China in September 2006.

Ian Woo

President and Chief Financial Officer

Prior to joining our Company in June 2018, Mr. Woo served as a managing director in the healthcare advisory team at Lazard Frères & Co. LLC (“LFNY”), a subsidiary of the financial advisory and asset management firm Lazard Ltd (NYSE: LAZ). Mr. Woo joined LFNY in March 2005 and was based in New York until June 2018, other than from January 2012 to June 2016 during which period he worked at Lazard Asia (Hong Kong) Limited, LFNY’s Hong Kong office and an SFC licensed corporation.

Mr. Woo also serves as an Independent Director and Chair of the Audit Committee at Prenetics Global Limited, and as Board Advisor at the Columbia University Mailman School of Public Health.

Mr. Woo received his bachelor’s degree in biology from Tufts University in the United States in May 1994, his master’s degree in cellular, molecular and biomedical studies from the Columbia University Graduate School of Arts and Sciences in the United States in May 1998 and his master of business administration degree from the Columbia University Graduate School of Business in the United States in May 2003.

Jason Brown, Ph.D.

Chief Business Officer

Prior to joining our Company from July 2007 to June 2016, Dr. Brown held multiple positions at Thomas, McNerney & Partners, a healthcare venture firm that invests in life science and medical technology companies, and his last position held was partner. From June 2003 to June 2007, Dr. Brown was employed by Forward Ventures, a life science venture capital firm located in San Diego, California, and his last position held was associate.

Dr. Brown received his bachelor’s degree in biochemistry and molecular biology from Purdue University in the United States in May 1993 and his Ph.D. in biology from the University of California, San Diego in the United States in June 2000.

Rico Liang

Chief Product Officer

Mr. Rico Liang has been appointed Chief Product Officer overseeing the Company’s medical affairs and marketing departments. Mr. Liang has more than two decades of experience in the pharmaceutical industry, especially in medical affairs, marketing & sales management, and clinical operation. He also has experience in helping build out from scratch a fully functional company in China with innovative and highly effective operation systems. Previously, he was general manager of Greater China at Brii Biosciences, responsible for commercialization, government affairs, regulatory affairs, and medical Affairs. Prior to Brii, Mr. Liang held several leadership positions in Gilead China including Executive Director and was responsible for commercial strategy design and implementation, and leading the marketing team to successfully deliver product launches for innovative treatments. In addition, he held various positions in Roche, Novartis and Amgen.

Wei Jennifer Yang, Ph.D

Chief Scientific Officer

Dr. Yang has two decades of leadership experience in drug discovery and development at global pharmaceutical companies.  Prior to joining Everest, Dr. Yang served as vice president and head of China for Johnson & Johnson’s Lung Cancer Initiative where she established and led a cross-sector research and development (R&D) organization for the creation of innovative solutions for lung cancer prevention, interception and cure. Jennifer transitioned into this role from Janssen (China) Research & Development Organization, where she was the head of Discovery Center.  Prior to joining Johnson and Johnson, Dr. Yang held global leadership positions at Eli Lilly and Company and Pfizer Inc Oncology Research Unit in the United States.

Dr. Yang holds a Ph.D. in molecular biology and human genetics from the Eccles Institute of Human Genetics at the University of Utah, a Master’s degree in immunology and microbiology from Southern Illinois University, and a Bachelor of Science degree in microbiology from Fudan University in China.

Sandra Zeng

Chief Medical Officer

Ms. Sandra Zeng has been appointed Chief Medical Officer in charge of the clinical development team and cross function collaboration to bring more in-house developed and in-licensed innovative products in China. She has more than 20 years’ experience and achievements in oncology and immunology industries across diversified functions, including pharmaceutical discovery, development and medical affairs in U.S. and China. Most recently, she served as Global Development Program Lead in Hematology in Bristol Myers Squibb USA, leading a cross-function team to advance several programs through clinical development, regulatory submission, manufacturing and commercialization. She also led the programs from first-in-human, proof of concept to phase III completion and NDA filing. Prior to this, Ms. Zeng held several leadership positions in Celgene Corporation, Roche and Merck in both global headquarters and China units.